Different opinions on Oncothyreon

Cantor Fitzgerald downgrades Oncothyreon (ONTY) from Buy to Hold citing valuation. Yesterday's close of $3.89 near its price target of $4.

Stifel maintains its Buy rating and raises its price target from $3 to $6 citing the potential long-term label expansion of ARRY-380.

The company expects to burn $30M - $33M next year. It has enough cash to fund operations for the next 12 months.

48 mutual funds have positions, down from 102 last year.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs